Estrogen-Receptor Positive Breast Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: EST001 MIFTS: 45	Estrogen-Receptor Positive Breast Cancer Categories: Cancer diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Estrogen-Receptor Positive Breast Cancer

MalaCards integrated aliases for Estrogen-Receptor Positive Breast Cancer:

Name: Estrogen-Receptor Positive Breast Cancer ¹¹ ¹⁴ ¹⁶

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:0060075

EFO ¹⁶ EFO_1000649

Sources

Summaries for Estrogen-Receptor Positive Breast Cancer

Disease Ontology: ¹¹ A breast cancer that is characterized by the presence of estrogen receptors.

MalaCards based summary: Estrogen-Receptor Positive Breast Cancer is related to breast cancer and endometrial hyperplasia. An important gene associated with Estrogen-Receptor Positive Breast Cancer is HSPB8 (Heat Shock Protein Family B (Small) Member 8), and among its related pathways/superpathways are Gene expression (Transcription) and Disease. The drugs Cyclophosphamide and Lactitol have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and lymph node, and related phenotypes are Decreased viability and Increased shRNA abundance (Z-score > 2)

Sources

Related Diseases for Estrogen-Receptor Positive Breast Cancer

Diseases in the Estrogen-Receptor Positive Breast Cancer family:

Estrogen-Receptor Negative Breast Cancer

Diseases related to Estrogen-Receptor Positive Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 449)

#	Related Disease	Score	Top Affiliating Genes
1	breast cancer	31.1	TP53 PGR MIR125A KDM4C HSPB8 H2AC18
2	endometrial hyperplasia	30.9	TP53 PGR ESR1 CYP19A1 CCND1
3	vaginal discharge	30.8	PGR ESR1 CYP19A1
4	tubular adenocarcinoma	30.7	PGR ESR1 ERBB2
5	postmenopausal atrophic vaginitis	30.7	ESR1 CYP19A1
6	cribriform carcinoma	30.6	PGR ESR1 ERBB2 EGFR
7	body mass index quantitative trait locus 11	30.6	TP53 MIR125A KDM4C H2AC18 ESR1 CYP19A1
8	exanthem	30.6	H2AC18 ERBB2 EGFR AKT1
9	mucinous adenocarcinoma	30.6	U2AF1 TP53 ERBB2 EGFR
10	bilateral breast cancer	30.6	TP53 PGR ESR1 ERBB2 CYP19A1
11	adenocarcinoma	30.6	TP53 ERBB2 EGFR CDK4 CCND1 AKT1
12	sporadic breast cancer	30.5	TP53 PGR H2AC18 ESR1 ERBB2
13	small cell cancer of the lung	30.5	TP53 EGFR AKT1
14	premature menopause	30.4	TP53 PGR ESR1 ERBB2 CYP19A1 AKT1
15	ductal carcinoma in situ	30.4	TP53 PGR ESR1 ERBB2 EGFR CYP19A1
16	breast disease	30.3	U2AF1 TP53 PGR MIR125A KDM4C H2AC18
17	hypertrophy of breast	30.3	TP53 PGR ESR1 ERBB2 EGFR CYP19A1
18	breast ductal carcinoma	30.3	TP53 PGR ESR1 ERBB2 EGFR CYP19A1
19	estrogen-receptor negative breast cancer	30.3	TP53 PGR H2AC18 ESR1 ERBB2 EGFR
20	adenoid cystic carcinoma	30.2	TP53 PGR ERBB2 EGFR CDK4 CCND1
21	lung cancer susceptibility 3	30.2	U2AF1 TP53 MIR125A H2AC18 ERBB2 EGFR
22	female breast cancer	30.2	TP53 PGR ESR1 ERBB2 EGFR CYP19A1
23	endometrial cancer	30.1	TP53 PGR H2AC18 ESR1 ERBB2 EGFR
24	ovarian cancer	29.8	TP53 PGR MIR125A H2AC18 ESR1 ERBB2
25	breast adenocarcinoma	29.8	U2AF1 TP53 PGR H2AC18 ESR1 ERBB2
26	down syndrome	10.8
27	uterine corpus adenosarcoma	10.5	PGR ESR1
28	factor vii deficiency	10.5
29	ovarian cyst	10.4	PGR ESR1 CYP19A1
30	adult cystic nephroma	10.4	PGR ESR1
31	vagina leiomyosarcoma	10.4	PGR ESR1
32	scirrhous adenocarcinoma	10.4	PGR ERBB2
33	vulvar benign neoplasm	10.4	PGR ESR1
34	nipple carcinoma	10.4	PGR ESR1 ERBB2
35	breast mucinous cystadenocarcinoma	10.4	PGR ESR1 ERBB2
36	breast fibroadenosis	10.4	PGR ESR1 ERBB2
37	lipid-rich breast carcinoma	10.4	PGR ERBB2
38	bulbospinal polio	10.4	PGR ESR1 ERBB2
39	spinal polio	10.4	PGR ESR1 ERBB2
40	her2-receptor negative breast cancer	10.4	PGR ERBB2
41	diffuse peritoneal leiomyomatosis	10.4	PGR ESR1 CYP19A1
42	glycogen-rich clear cell breast carcinoma	10.4	PGR ESR1 ERBB2
43	peritoneal benign neoplasm	10.4	PGR ESR1 CYP19A1
44	breast cystic hypersecretory carcinoma	10.4	PGR ESR1 ERBB2
45	oncocytic breast carcinoma	10.4	PGR ESR1 ERBB2
46	progesterone resistance	10.4	PGR ESR1
47	breast squamous cell carcinoma	10.4	PGR ESR1 ERBB2
48	adenosquamous breast carcinoma	10.4	TP53 PGR
49	leiomyomatosis	10.4	PGR KDM4C ESR1
50	subserous uterine fibroid	10.4	PGR CYP19A1

Graphical network of the top 20 diseases related to Estrogen-Receptor Positive Breast Cancer:

Sources

Symptoms & Phenotypes for Estrogen-Receptor Positive Breast Cancer

GenomeRNAi Phenotypes related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

²⁵ (show all 37)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-1	10.16	EGFR
2	Decreased viability	GR00055-A-2	10.16	EGFR
3	Decreased viability	GR00107-A-1	10.16	HSPB8
4	Decreased viability	GR00221-A-1	10.16	AKT1 EGFR ESR1 HSPB8
5	Decreased viability	GR00221-A-2	10.16	AKT1 ESR1
6	Decreased viability	GR00221-A-3	10.16	AKT1 ERBB2
7	Decreased viability	GR00221-A-4	10.16	AKT1 EGFR ERBB2 ESR1 HSPB8
8	Decreased viability	GR00249-S	10.16	AKT1
9	Decreased viability	GR00301-A	10.16	HSPB8
10	Decreased viability	GR00386-A-1	10.16	ESR1
11	Decreased viability	GR00402-S-2	10.16	ESR1
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-120	9.81	U2AF1
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-121	9.81	EGFR
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-136	9.81	U2AF1
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-153	9.81	U2AF1
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-161	9.81	ERBB2
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-168	9.81	ERBB2
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-186	9.81	CBFB
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-207	9.81	ERBB2
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-21	9.81	EGFR
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-211	9.81	U2AF1
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-213	9.81	AKT1
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-214	9.81	EGFR
24	Increased shRNA abundance (Z-score > 2)	GR00366-A-32	9.81	ERBB2
25	Increased shRNA abundance (Z-score > 2)	GR00366-A-42	9.81	CBFB
26	Increased shRNA abundance (Z-score > 2)	GR00366-A-43	9.81	EGFR
27	Increased shRNA abundance (Z-score > 2)	GR00366-A-55	9.81	CBFB
28	Increased shRNA abundance (Z-score > 2)	GR00366-A-60	9.81	AKT1 ERBB2
29	Increased shRNA abundance (Z-score > 2)	GR00366-A-63	9.81	ERBB2
30	Increased shRNA abundance (Z-score > 2)	GR00366-A-70	9.81	AKT1
31	Increased shRNA abundance (Z-score > 2)	GR00366-A-79	9.81	CBFB
32	Increased shRNA abundance (Z-score > 2)	GR00366-A-85	9.81	AKT1 CDK4 EGFR ERBB2 U2AF1
33	Increased shRNA abundance (Z-score > 2)	GR00366-A-87	9.81	ERBB2
34	Increased shRNA abundance (Z-score > 2)	GR00366-A-88	9.81	CBFB
35	Increased shRNA abundance (Z-score > 2)	GR00366-A-89	9.81	U2AF1
36	Increased shRNA abundance (Z-score > 2)	GR00366-A-91	9.81	EGFR U2AF1
37	Increased cell viability after pRB stimulation	GR00230-A-1	9.26	AKT1 CDK4 EGFR ERBB2

MGI Mouse Phenotypes related to Estrogen-Receptor Positive Breast Cancer:

⁴⁵ (show all 13)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.32	AKT1 CBFB CCND1 CDK4 CYP19A1 EGFR
2	neoplasm	MP:0002006	10.26	AKT1 CBFB CCND1 CDK4 EGFR ERBB2
3	normal	MP:0002873	10.21	AKT1 CBFB CCND1 CDK4 CYP19A1 EGFR
4	endocrine/exocrine gland	MP:0005379	10.2	AKT1 CBFB CCND1 CDK4 CYP19A1 EGFR
5	cellular	MP:0005384	10.18	AKT1 CBFB CCND1 CDK4 CYP19A1 EGFR
6	immune system	MP:0005387	10.17	AKT1 CBFB CCND1 CDK4 CYP19A1 CYP2D6
7	muscle	MP:0005369	10.15	AKT1 CDK4 CYP19A1 EGFR ERBB2 ESR1
8	cardiovascular system	MP:0005385	10.15	AKT1 CBFB CCND1 CDK4 CYP19A1 EGFR
9	digestive/alimentary	MP:0005381	10.03	CBFB CCND1 CDK4 CYP19A1 EGFR ERBB2
10	respiratory system	MP:0005388	9.86	AKT1 CBFB CCND1 EGFR ERBB2 ESR1
11	skeleton	MP:0005390	9.85	AKT1 CBFB CCND1 CDK4 CYP19A1 EGFR
12	hematopoietic system	MP:0005397	9.77	AKT1 CBFB CCND1 CDK4 CYP19A1 EGFR
13	integument	MP:0010771	9.47	AKT1 CBFB CCND1 CDK4 CYP19A1 CYP2D6

Sources

Drugs & Therapeutics for Estrogen-Receptor Positive Breast Cancer

Drugs for Estrogen-Receptor Positive Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 147)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Cyclophosphamide

Approved, Investigational

Phase 4

50-18-0, 6055-19-2

2907

Lactitol

Approved, Investigational

Phase 4

585-86-4

157355

Epirubicin

Approved

Phase 4

56420-45-2

41867

Docetaxel

Approved, Investigational

Phase 4

114977-28-5

148124

Immunologic Factors

Phase 4

Immunosuppressive Agents

Phase 4

Antirheumatic Agents

Phase 4

Anti-Bacterial Agents

Phase 4

Alkylating Agents

Phase 4

Antineoplastic Agents, Alkylating

Phase 4

Antimitotic Agents

Phase 4

Tubulin Modulators

Phase 4

Antibiotics, Antitubercular

Phase 4

Letrozole

Approved, Investigational

Phase 3

112809-51-5

3902

Sodium citrate

Approved, Investigational

Phase 3

68-04-2

23431961

Capecitabine

Approved, Investigational

Phase 2, Phase 3

154361-50-9

60953

Exemestane

Approved, Investigational

Phase 2, Phase 3

107868-30-4

60198

Anastrozole

Approved, Investigational

Phase 2, Phase 3

120511-73-1

2187

Tamoxifen

Approved

Phase 2, Phase 3

10540-29-1, 54965-24-1

2733526

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 3

77-92-9

311

Tryptophan

Approved, Nutraceutical, Withdrawn

Phase 3

73-22-3

6305

Citrate

Phase 3

Psychotropic Drugs

Phase 3

Antidepressive Agents

Phase 3

Antineoplastic Agents, Hormonal

Phase 2, Phase 3

Estrogen Receptor Modulators

Phase 2, Phase 3

Selective Estrogen Receptor Modulators

Phase 2, Phase 3

Sorafenib

Approved, Investigational

Phase 2

284461-73-0

216239

Metformin

Approved

Phase 2

1115-70-4, 657-24-9

4091

Simvastatin

Approved

Phase 2

79902-63-9

54454

Lenograstim

Approved, Investigational

Phase 2

135968-09-1

Gefitinib

Approved, Investigational

Phase 2

184475-35-2

123631

Busulfan

Approved, Investigational

Phase 2

55-98-1

2478

Melphalan

Approved

Phase 2

148-82-3

4053 460612

Aldesleukin

Approved

Phase 2

110942-02-4

Thiotepa

Approved, Investigational

Phase 2

52-24-4

5453

Sargramostim

Approved, Investigational

Phase 2

123774-72-1

Cisplatin

Approved

Phase 2

15663-27-1

2767 5702198 441203

Zoledronic acid

Approved

Phase 2

118072-93-8

68740

Dasatinib

Approved, Investigational

Phase 2

302962-49-8

3062316

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 2

23593-75-1

2812

Caffeine

Approved

Phase 2

58-08-2

2519

Calcium polycarbophil

Approved

Phase 2

126040-58-2

Leuprolide

Approved, Investigational

Phase 2

53714-56-0

657181

Avelumab

Approved, Investigational

Phase 2

1537032-82-8

Estradiol

Approved, Investigational, Vet_approved

Phase 2

50-28-2

5757

Polyestradiol phosphate

Approved

Phase 2

28014-46-2

Decitabine

Approved, Investigational

Phase 2

2353-33-5

451668

Atezolizumab

Approved, Investigational

Phase 2

1380723-44-3

Interventional clinical trials:

(show top 50) (show all 89)

#	Name	Status	NCT ID	Phase	Drugs
1	Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy for Postmenopausal Estrogen Receptor-positive Breast Cancer: a Prospective Randomized Controlled Double-blind Phase IV Trial	Not yet recruiting	NCT04137640	Phase 4	palbociclib combined with letrozole;epirubicin combined with cyclophosphamide and sequential docetaxel
2	A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg Daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer	Completed	NCT00265759	Phase 3	anastrozole;exemestane;letrozole
3	Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study	Active, not recruiting	NCT01953588	Phase 3	fulvestrant;anastrozole
4	A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women With Endocrine Responsive Breast Cancer	Active, not recruiting	NCT00066690	Phase 3	Exemestane;Tamoxifen;Triptorelin
5	A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer	Active, not recruiting	NCT02947685	Phase 3	palbociclib;trastuzumab;pertuzumab;letrozole;Anastrozole;Exemestane;Fulvestrant
6	Randomized Phase II/III Study of Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic Estrogen Receptor Positive Breast Cancer	Terminated	NCT00684216	Phase 2, Phase 3	capecitabine;hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)
7	Letrozole With or Without Metronomic Capecitabine in First Line Treatment of Patients With ER-positive HER2 Negative Advanced Breast Cancer: A Randomized Phase II Study.	Unknown status	NCT04571437	Phase 2	Capecitabine;Letrozole 2.5mg
8	A Randomized Phase II Study of Fulvestrant in Combination With the Dual mTOR Inhibitor AZD2014 or Everolimus or Fulvestrant Alone in Estrogen Receptor-positive Advanced or Metastatic Breast Cancer	Unknown status	NCT02216786	Phase 2	AZD2014;Everolimus;Fulvestrant
9	Letrozole Plus Oral Cyclophosphamide Plus/Minus Sorafenib as Primary Systemic Treatment in Post-menopausal, Estrogen Receptor Positive, Breast Cancer Patients	Unknown status	NCT00954135	Phase 2	letrozolo+cyclophosphamide;letrozolo+sorafenib+cyclophosphamide
10	Single Arm Phase 2 Study of Metformin and Simvastatin in Addition to Fulvestrant in Metastatic Estrogen Receptor Positive Breast Cancer	Unknown status	NCT03192293	Phase 2	Metformin/Simvastatin/Fulvestrant
11	Phase II Randomized Trial of Mugard Compared With Best Supportive Care for Prevention and Treatment of Stomatitis in Women With Hormone Receptor Positive Breast Cancer Initiating Treatment With Everolimus-based Endocrine Therapy.	Completed	NCT02015559	Phase 2	mucoadhesive oral wound rinse
12	Open Label, Phase II Trial of Neoadjuvant TAK-228 Plus Tamoxifen in Patients With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer	Completed	NCT02988986	Phase 2	TAK-228;Tamoxifen
13	A Phase 2, Randomized, Double-Blind, Multicenter Study of Exemestane With and Without SNDX-275 in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer, Progressing on Treatment With a Non-Steroidal Aromatase Inhibitor	Completed	NCT00676663	Phase 2	entinostat;exemestane;Placebo
14	Adjuvant Therapy for High-Risk Localized Breast Cancer Using Weekly Adriamycin + Daily Oral Cytoxan With Continuous G-CSF Support for 12 Weeks Followed by Weekly Abraxane™ for 12 Weeks With Concurrent Herceptin for Subjects With HER-2/Neu Positive Disease, Phase II	Completed	NCT00407888	Phase 2	doxorubicin hydrochloride;cyclophosphamide;paclitaxel albumin-stabilized nanoparticle formulation
15	A Study of Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel as Neoadjuvant Therapy for Resectable, Hormone Receptor Negative or Hormone Receptor Positive, HER-2/Neu Positive Breast Cancer Followed by a Novel Regimen of Capecitabine, Methotrexate and Vinorelbine for Patients Who Do Not Have Either a Macroscopic or Microscopic Pathologic Complete Response, a Phase II Study	Completed	NCT00194779	Phase 2	doxorubicin hydrochloride;cyclophosphamide;paclitaxel;capecitabine;methotrexate;vinorelbine tartrate;tamoxifen citrate;letrozole
16	A Phase 2 Study of [18F] Fluoroestradiol (FES) as a Marker of Hormone Sensitivity of Metastatic Breast Cancer	Completed	NCT00602043	Phase 2
17	Pre-surgical Phase IIb Trial of Transdermal 4-Hydroxytamoxifen vs. Oral Tamoxifen in Women With Ductal Carcinoma in Situ of the Breast	Completed	NCT00952731	Phase 2	oral placebo;afimoxifene;tamoxifen citrate;placebo gel
18	A Phase II Trial of Tipifarnib (R115777, Zarnestra™) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Hormone Receptor-Positive Breast Cancer	Completed	NCT00082810	Phase 2	fulvestrant;tipifarnib
19	A Randomized Phase II Trial of Combination Anastrozole (NSC #719344) Plus ZD1839 (Iressa, NSC #715055, IND #61187) and of Combination Fulvestrant (NSC #719276) Plus ZD1839 in the Treatment of Postmenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer	Completed	NCT00057941	Phase 2	anastrozole;gefitinib;fulvestrant
20	A Phase II Trial for Patients With Inflammatory (Stage IIIB) and Responsive Metastatic Stage IV Breast Cancer Using Busulfan, Melphalan and Thiotepa Followed by Autologous or Syngeneic PBSC Rescue and 12 Weeks of Post-Engraftment Immunotherapy With Low-Dose IL-2 and GM-CSF	Completed	NCT00003199	Phase 2	tamoxifen citrate;busulfan;thiotepa;melphalan
21	Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer	Completed	NCT01037790	Phase 2	PD-0332991
22	A Phase II Prospective Pilot Study Evaluating Efficacy of Intravenous Zoledronic Acid Prophylaxis for Prevention of Aromatase Inhibitor Associated Musculoskeletal Symptoms: ZAP-AIMSS Trial	Completed	NCT01194440	Phase 2	letrozole;zoledronic acid
23	A Randomized, Double-Blind, Multi-Center Phase II Trial of Exemestane (AromasinÂ®) Plus Dasatinib Versus Exemestane Plus Placebo in Advanced Estrogen Receptor-Positive Breast Cancer After Disease Progression on a Non-Steroidal Aromatase Inhibitor (NSAI)	Completed	NCT00767520	Phase 2	Exemestane + Dasatinib;Exemestane + Placebo
24	A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients	Completed	NCT01605396	Phase 2	Ridaforolimus;Dalotuzumab;Exemestane
25	A Randomized, Open-Label, Multicenter, Phase II Study Comparing the Effects on Proliferation and the Efficacy and Tolerability of Fulvestrant (FASLODEX®) 500 mg With Fulvestrant (FASLODEX®) 250 mg When Given as Neoadjuvant Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer (T2, 3, 4b, N0-3, M0).	Completed	NCT00093002	Phase 2	Fulvestrant
26	A Two-Part Adaptive, Randomized Trial of Ridaforolimus in Combination With Dalotuzumab Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Breast Cancer Patients	Completed	NCT01234857	Phase 2	ridaforolimus + dalotuzumab;exemestane;ridaforolimus;dalotuzumab
27	Phase II Open Label Study of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic, Estrogen Receptor Positive Breast Cancer, After Failure of Tamoxifen and/or Anastrozole and/or Letrozole and/or Fulvestrant and/or Exemestane	Completed	NCT01231659	Phase 2	Everolimus;Letrozole
28	REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy	Recruiting	NCT01984138	Phase 2	ESTRING;Replens
29	A Randomized Phase 2 Non-inferiority Trial of (Z)-Endoxifen and Exemestane + Goserelin as Neoadjuvant Treatment in Premenopausal Women With ER+/HER2- Breast Cancer	Recruiting	NCT05607004	Phase 2	Z-endoxifen;exemestane;goserelin
30	A Phase 2 Study of VLS-101 in Patients With Solid Tumors	Recruiting	NCT04504916	Phase 2	Zilovertamab vedotin
31	Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer	Recruiting	NCT05076695	Phase 2	Palbociclib;trastuzumab;pyrotinib;fulvestrant
32	Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition	Recruiting	NCT04965688	Phase 2	Drug determined by treating oncologist based on recommendation from systems biology analysis.
33	A Pilot Study of IMMUNe mOdulation in Early Stage Estrogen Receptor Positive Breast Cancer Treated With neoADjuvant Avelumab, Palbociclib, and Endocrine Therapy: The ImmunoADAPT Study	Recruiting	NCT03573648	Phase 2	Avelumab;Endocrine therapy;Palbociclib
34	A Single Arm Phase II Study of Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-016	Active, not recruiting	NCT02668666	Phase 2	Palbociclib;Tamoxifen
35	A Phase 1b/2 Randomised Placebo Controlled Trial of Fulvestrant +/- AZD5363 in Postmenopausal Women With Advanced Breast Cancer Previously Treated With a Third Generation Aromatase Inhibitor	Active, not recruiting	NCT01992952	Phase 1, Phase 2	AZD5363;Placebo;Fulvestrant
36	T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy	Active, not recruiting	NCT02957968	Phase 2	Doxorubicin;Cyclophosphamide;Paclitaxel;Carboplatin;Decitabine;Pembrolizumab
37	A Phase 1-2 Multicenter, Open Label Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer	Active, not recruiting	NCT03250676	Phase 1, Phase 2	H3B-6545
38	[18F]Fluoroestradiol (FES) PET/CT Imaging to Evaluate in Vivo ER in Endocrine Refractory Metastatic Breast Cancer	Active, not recruiting	NCT02409316	Phase 2	[18F]FES
39	A Phase II Study Investigating Preoperative Combination Strategies for Immunotherapy in Patients With Untreated, Operable ER+, HER2-negative Primary Breast Cancer	Active, not recruiting	NCT03395899	Phase 2	Atezolizumab;Cobimetinib;Ipatasertib;Bevacizumab
40	A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer	Active, not recruiting	NCT03633331	Phase 2	Palbociclib;Letrozole;Fulvestrant
41	PRe-operative ESTradiOl Window of Opportunity Study in Post-Menopausal Women With Newly Diagnosed ER Positive Breast Cancer	Active, not recruiting	NCT02238808	Phase 2	Estradiol
42	A Phase II Trial to Correlate Early Clinical Response to Pathologic Outcome With Neoadjuvant Systemic Therapy in Patients With Early Stage Breast Cancer	Not yet recruiting	NCT05020860	Phase 2	Paclitaxel;Carboplatin;Trastuzumab;Pertuzumab;Doxorubicin;Cyclophosphamide
43	A Pilot Study of 68-Ga-RM2 PET/MRI in the Evaluation of Patients With Estrogen Receptor-Positive Breast Cancer	Suspended	NCT03831711	Phase 1, Phase 2	Gallium Ga 68-labeled GRPR Antagonist BAY86-7548
44	Phase II Study of the Combination of Pembrolizumab, Letrozole, and Palbociclib in Postmenopausal Patients With Newly Diagnosed Metastatic Estrogen Receptor Positive Breast Cancer	Suspended	NCT02778685	Phase 2	Fulvestrant;Letrozole;Palbociclib
45	A Phase II Non Randomized Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)	Terminated	NCT02000375	Phase 2	DHEA
46	Phase II Study of Everolimus Beyond Progression in Postmenopausal Women With Advanced, Hormone Receptor Positive Breast Cancer	Terminated	NCT02269670	Phase 2	everolimus;anastrozole;letrozole;tamoxifen citrate;fulvestrant;megestrol acetate
47	Phase II Evaluation of Real-Time, Pharmacokinetically Guided Everolimus in Patients With Hormone Receptor Positive Breast Cancer, Pancreatic Neuroendocrine Tumors (PNET), and Renal Cell Carcinoma	Terminated	NCT02273752	Phase 2	Everolimus
48	Neoadjuvant Complete Hormonal Blockade Followed by Neoadjuvant Chemotherapy for Resectable Hormone Receptor Positive, HER-2/Neu Negative Breast Cancer, A Phase II Study	Terminated	NCT00194792	Phase 2	exemestane;triptorelin pamoate;capecitabine;methotrexate;vinorelbine tartrate;paclitaxel
49	A Multisite International Collaborative Phase 2 Study of Neoadjuvant Goserelin and a Non-steroidal Aromatase Inhibitor for Premenopausal Women With Estrogen Receptor Positive HER2 Negative Clinical Stage 2 and 3 Breast Cancer	Terminated	NCT01368263	Phase 2	goserelin acetate;letrozole;anastrozole;chemotherapy
50	Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer	Terminated	NCT01394211	Phase 2	anastrozole;pazopanib hydrochloride

Search NIH Clinical Center for Estrogen-Receptor Positive Breast Cancer

Sources

Genetic Tests for Estrogen-Receptor Positive Breast Cancer

Sources

Anatomical Context for Estrogen-Receptor Positive Breast Cancer

Organs/tissues related to Estrogen-Receptor Positive Breast Cancer:

MalaCards : Breast, Bone, Lymph Node, Bone Marrow, Prostate, T Cells, Endothelial

Sources

Publications for Estrogen-Receptor Positive Breast Cancer

Articles related to Estrogen-Receptor Positive Breast Cancer:

(show top 50) (show all 1493)

#	Title	Authors	PMID	Year
1	Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor-Positive Breast Cancer. ⁶²	Jayasekera J...Isaacs C	36455167	2022
2	CCAT2 knockdown inhibits cell growth, and migration and promotes apoptosis through regulating the hsa-mir-145-5p/AKT3/mTOR axis in tamoxifen-resistant MCF7 cells. ⁶²	Moradi F...Sadeghizadeh M	36375570	2022
3	Carbidopa suppresses estrogen receptor-positive breast cancer via AhR-mediated proteasomal degradation of ERα. ⁶²	Chen Z...Kou L	36070108	2022
4	Prolylcarboxypeptidase promotes IGF1R/HER3 signaling and is a potential target to improve endocrine therapy response in estrogen receptor positive breast cancer. ⁶²	Duan L...Maki CG	36332175	2022
5	Pharmacological targeting of androgen receptor elicits context-specific effects in estrogen receptor-positive breast cancer. ⁶²	Wei L...Wang L	36469363	2022
6	Ceramide kinase confers tamoxifen resistance in estrogen receptor-positive breast cancer by altering sphingolipid metabolism. ⁶²	Huang C...Wong PP	36410675	2022
7	Correction to: Nogo-B receptor increases glycolysis and the paclitaxel resistance of estrogen receptor-positive breast cancer via the HIF-1α-dependent pathway. ⁶²	Liu C...Fan Z	36376422	2022
8	Etoposide in combination with erastin synergistically altered iron homeostasis and induced ferroptotic cell death through regulating IREB2/FPN1 expression in estrogen receptor positive-breast cancer cells. ⁶²	Ozkan E...Bakar-Ates F	36442526	2022
9	One Way or Another: An Oligorecurrence After an Oligometastasis of an Estrogen Receptor-Positive Breast Cancer. ⁶²	Goodman CR...Strauss JB	36244388	2022
10	ESR1 activating mutations: From structure to clinical application. ⁶²	Grinshpun A...Jeselsohn R	36336145	2022
11	Comparison of the Nottingham Prognostic Index and OncotypeDX© recurrence score in predicting outcome in estrogen receptor positive breast cancer. ⁶²	Kerin EP...Kerin MJ	36335747	2022
12	A genome-wide association study of mammographic texture variation. ⁶²	Liu Y...Jiang X	36344993	2022
13	Long-term exposure to nitrogen dioxide air pollution and breast cancer risk: A nested case-control within the French E3N cohort study. ⁶²	Amadou A...Fervers B	36435283	2022
14	Synthesis and Anticancer Evaluation of Novel Indole Based Arylsulfonylhydrazides against Human Breast Cancer Cells. ⁶²	Gaur A...Azam A	36440122	2022
15	Long-Term Outcome of Sustained Endocrine Monotherapy for Elderly Breast Cancer Patients. ⁶²	Gooijer SA...van Dalen T	36326972	2022
16	Overexpression of Estrogen Receptor α in Mammary Glands of Aging Mice Is Associated with a Proliferative Risk Signature and Generation of Estrogen Receptor α-Positive Mammary Adenocarcinomas. ⁶²	Furth PA...Flaws JA	36464513	2022
17	Exploring the potential of dried plasma collection cards for liquid chromatography coupled with tandem mass spectrometry quantitation of giredestrant in human plasma. ⁶²	Tang Y...Wang J	36417291	2022
18	Bioavailability and Pharmacokinetics of Endoxifen in Female Rats and Dogs: Evidence to Support the Use of Endoxifen to Overcome the Limitations of CYP2D6-Mediated Tamoxifen Metabolism. ⁶²	Koubek EJ...Reid JM	36351835	2022
19	Stabilization of estrogen receptor α by USP37 contributes to the progression of breast cancer. ⁶²	Cao J...Tang J	36221793	2022
20	The ubiquitin ligase RNF2 stabilizes ERα and modulates breast cancer progression. ⁶²	Yuan L...Li H	36271315	2022
21	Pathobiologic Stratification of Oncotype DX Recurrence Scores and Comparative Validation of 3 Surrogate Models. ⁶²	Mohamed A...Geradts J	35119458	2022
22	Association of HSD3B1 Genotype and Clinical Outcomes in Postmenopausal Estrogen-Receptor-Positive Breast Cancer. ⁶²	Flanagan MR...Gadi VK	35776258	2022
23	Nogo-B receptor increases glycolysis and the paclitaxel resistance of estrogen receptor-positive breast cancer via the HIF-1α-dependent pathway. ⁶²	Liu C...Fan Z	36241702	2022
24	ASO Visual Abstract: Association of HSD3B1 Genotype and Clinical Outcomes in Postmenopausal Estrogen Receptor-Positive Breast Cancer. ⁶²	Flanagan MR...Gadi VK	35980550	2022
25	Molecular Imaging for Estrogen Receptor-Positive Breast Cancer: Clinical Applications of Whole Body and Dedicated Breast Positron Emission Tomography. ⁶²	Goodman K...Mukhtar RA	36243494	2022
26	Dietary exposure to acrylamide and breast cancer risk: results from the NutriNet-Santé cohort. ⁶²	Bellicha A...Touvier M	36055962	2022
27	Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study. ⁶²	Acs B...Rimm DL	35729220	2022
28	Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial. ⁶²	Vliek SB...Linn SC	35442755	2022
29	A novel oncogenic enhancer of estrogen receptor-positive breast cancer. ⁶²	Bao C...Lu W	36159594	2022
30	High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer. ⁶²	Palafox M...Serra V	36071033	2022
31	Molecular testing opportunities on cytology effusion specimens: the pre-analytic effects of various body fluid cytology preparation methods on RNA extraction quality and targeted sequencing. ⁶²	Sura GH...Symmans WF	36270909	2022
32	HSF1 Can Prevent Inflammation following Heat Shock by Inhibiting the Excessive Activation of the ATF3 and JUN&FOS Genes. ⁶²	Janus P...Widlak W	36010586	2022
33	MiR-4458-loaded gelatin nanospheres target COL11A1 for DDR2/SRC signaling pathway inactivation to suppress the progression of estrogen receptor-positive breast cancer. ⁶²	Liu J...Zhang CY	35792605	2022
34	Testing Endocrine Response for Managing Primary Estrogen Receptor-Positive Breast Cancer. ⁶²	Dowsett M	35412846	2022
35	Sustained Tumor Regression With Zenocutuzumab, a Bispecific Antibody Targeting Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 Signaling, in NRG1 Fusion-Positive, Estrogen Receptor-Positive Breast Cancer After Progression on a Cyclin-Dependent Kinase 4/6 Inhibitor. ⁶²	Fontana E...Arkenau HT	35977350	2022
36	The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer. ⁶²	Isnaldi E...Desmedt C	35927391	2022
37	Time to Chemotherapy for Patients With Estrogen Receptor-Positive Breast Cancer and Cyclin-Dependent Kinase 4 and 6 Inhibitor Use. ⁶²	Endo Y...Iwata H	36031754	2022
38	Epithelial-mesenchymal plasticity determines estrogen receptor positive breast cancer dormancy and epithelial reconversion drives recurrence. ⁶²	Aouad P...Brisken C	36008376	2022
39	S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer. ⁶²	Mo H...Ma F	36042494	2022
40	Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor-Positive Breast Cancer. ⁶²	Xia Y...Turnbull A	35653148	2022
41	Breast Nurse Intervention to Improve Adherence to Endocrine Therapy Among Breast Cancer Patients in South Ethiopia. ⁶²	Getachew S...Kantelhardt EJ	35524760	2022
42	Molecular Characterization of Exosomes for Subtype-Based Diagnosis of Breast Cancer. ⁶²	Cao Y...Li G	35802880	2022
43	The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events. ⁶²	Timilsina S...Kaklamani V	35568265	2022
44	High SLC20A1 Expression Is Associated With Poor Prognosis for Radiotherapy of Estrogen Receptor-positive Breast Cancer. ⁶²	Onaga C...Akimoto K	35813014	2022
45	Effects of iron modulation on mesenchymal stem cell-induced drug resistance in estrogen receptor-positive breast cancer. ⁶²	Buschhaus JM...Luker GD	35732800	2022
46	Screening of and mechanism underlying the action of serum- and glucocorticoid-regulated kinase 3-targeted drugs against estrogen receptor-positive breast cancer. ⁶²	Zhou D...Zhou W	35569550	2022
47	PET Imaging of Estrogen Receptors for Gynecological Tumors. ⁶²	Tsujikawa T...Okazawa H	35675139	2022
48	The ELEANOR noncoding RNA expression contributes to cancer dormancy and predicts late recurrence of estrogen receptor-positive breast cancer. ⁶²	Fukuoka M...Saitoh N	35415910	2022
49	Tailoring the Omission of Radiotherapy for Early-Stage Breast Cancer Based on Tumor Biology. ⁶²	Allen SG...Jagsi R	35688518	2022
50	Establishment and transcriptome characterization of tamoxifen-resistant canine mammary gland tumor cells. ⁶²	Xu E...Liu Y	35193047	2022

Sources

Genes for Estrogen-Receptor Positive Breast Cancer

Genes related to Estrogen-Receptor Positive Breast Cancer (0 elite genes):

(show all 38)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	HSPB8	Heat Shock Protein Family B (Small) Member 8	Protein Coding	21.42	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
2	CBFB	Core-Binding Factor Subunit Beta	Protein Coding	8.48	GeneCards inferred via : Summaries (show sections)
3	ESR1	Estrogen Receptor 1	Protein Coding	8.46	DISEASES inferred ¹⁴
4	MIR1266	MicroRNA 1266	RNA Gene	8.04	DISEASES inferred ¹⁴ ¹⁴
5	ISG20	Interferon Stimulated Exonuclease Gene 20	Protein Coding	7.99	GeneCards inferred via : Expressions (show sections)
6	HNRNPCL2	Heterogeneous Nuclear Ribonucleoprotein C Like 2	Protein Coding	7.76	DISEASES inferred ¹⁴ ¹⁴
7	CYP19A1	Cytochrome P450 Family 19 Subfamily A Member 1	Protein Coding	7.68	DISEASES inferred ¹⁴
8	NENF	Neudesin Neurotrophic Factor	Protein Coding	7.52	GeneCards inferred via : Functions (show sections)
9	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	7.31	DISEASES inferred ¹⁴
10	KDM4C	Lysine Demethylase 4C	Protein Coding	7.3	DISEASES inferred ¹⁴ ¹⁴
11	PGR	Progesterone Receptor	Protein Coding	6.96	DISEASES inferred ¹⁴
12	MIR125A	MicroRNA 125a	RNA Gene	6.47	DISEASES inferred ¹⁴ ¹⁴
13	H2AC18	H2A Clustered Histone 18	Protein Coding	6.44	DISEASES inferred ¹⁴ ¹⁴
14	CYP2D6	Cytochrome P450 Family 2 Subfamily D Member 6	Protein Coding	6.42	DISEASES inferred ¹⁴
15	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	6.35	DISEASES inferred ¹⁴
16	U2AF1	U2 Small Nuclear RNA Auxiliary Factor 1	Protein Coding	6.34	DISEASES inferred ¹⁴ ¹⁴
17	CDK4	Cyclin Dependent Kinase 4	Protein Coding	6.33	DISEASES inferred ¹⁴
18	TP53	Tumor Protein P53	Protein Coding	6.1	DISEASES inferred ¹⁴
19	CCND1	Cyclin D1	Protein Coding	6.08	DISEASES inferred ¹⁴
20	EGFR	Epidermal Growth Factor Receptor	Protein Coding	6.05	DISEASES inferred ¹⁴
21	ORAI3	ORAI Calcium Release-Activated Calcium Modulator 3	Protein Coding	5.97	DISEASES inferred ¹⁴
22	BRCA1	BRCA1 DNA Repair Associated	Protein Coding	5.87	DISEASES inferred ¹⁴
23	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	5.87	DISEASES inferred ¹⁴
24	ESR2	Estrogen Receptor 2	Protein Coding	5.84	DISEASES inferred ¹⁴
25	SLC6A14	Solute Carrier Family 6 Member 14	Protein Coding	5.83	DISEASES inferred ¹⁴
26	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	5.83	DISEASES inferred ¹⁴
27	BCL2	BCL2 Apoptosis Regulator	Protein Coding	5.73	DISEASES inferred ¹⁴
28	PTEN	Phosphatase And Tensin Homolog	Protein Coding	5.6	DISEASES inferred ¹⁴
29	FOXA1	Forkhead Box A1	Protein Coding	5.57	DISEASES inferred ¹⁴
30	AR	Androgen Receptor	Protein Coding	5.55	DISEASES inferred ¹⁴
31	IGF1	Insulin Like Growth Factor 1	Protein Coding	5.55	DISEASES inferred ¹⁴
32	IGF1R	Insulin Like Growth Factor 1 Receptor	Protein Coding	5.54	DISEASES inferred ¹⁴
33	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	5.5	DISEASES inferred ¹⁴
34	EGF	Epidermal Growth Factor	Protein Coding	5.41	DISEASES inferred ¹⁴
35	STAT3	Signal Transducer And Activator Of Transcription 3	Protein Coding	5.4	DISEASES inferred ¹⁴
36	ACTB	Actin Beta	Protein Coding	5.38	DISEASES inferred ¹⁴
37	SRC	SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase	Protein Coding	5.37	DISEASES inferred ¹⁴
38	BRCA2	BRCA2 DNA Repair Associated	Protein Coding	5.37	DISEASES inferred ¹⁴

Sources

Variations for Estrogen-Receptor Positive Breast Cancer

Sources

Expression for Estrogen-Receptor Positive Breast Cancer

Search GEO for disease gene expression data for Estrogen-Receptor Positive Breast Cancer.

Sources

Pathways for Estrogen-Receptor Positive Breast Cancer

Pathways related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 62)

#	Super pathways	Score	Top Affiliating Genes
1	Gene expression (Transcription) ⁶⁶ Show member pathways Generic Transcription Pathway ⁶⁶ RNA Polymerase II Transcription ⁶⁶	14.08	AKT1 CBFB CCND1 CDK4 EGFR ERBB2
2	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.81	TP53 H2AC18 ESR1 ERBB2 EGFR CYP19A1
3	Signal Transduction ⁶⁶	13.68	AKT1 CBFB CCND1 CDK4 EGFR ERBB2
4	ESR-mediated signaling ⁶⁶ Show member pathways Estrogen-dependent gene expression ⁶⁶ RUNX1 regulates estrogen receptor mediated transcription ⁶⁶ Signaling by Nuclear Receptors ⁶⁶	12.91	PGR H2AC18 ESR1 EGFR CCND1 CBFB
5	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.84	PGR ESR1 ERBB2 EGFR AKT1
6	Pre-NOTCH Expression and Processing ⁶⁶ Show member pathways Defective LFNG causes SCDO3 ⁶⁶ Pre-NOTCH Processing in Golgi ⁶⁶ Pre-NOTCH Processing in the Endoplasmic Reticulum ⁶⁶ Pre-NOTCH Transcription and Translation ⁶⁶ Signaling by NOTCH ⁶⁶	12.77	TP53 H2AC18 EGFR CCND1 AKT1
7	Malignant pleural mesothelioma ⁷⁴	12.68	TP53 EGFR CDK4 CCND1 AKT1
8	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.64	TP53 ERBB2 EGFR CDK4 CCND1 AKT1
9	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.5	TP53 ERBB2 EGFR AKT1
10	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.44	TP53 ERBB2 EGFR AKT1
11	WNT Signaling ⁶⁴	12.43	TP53 CDK4 CCND1 AKT1
12	Development Dopamine D2 receptor transactivation of EGFR ²² Show member pathways Chemotaxis CXCR4 signaling pathway ²² Development Alpha-2 adrenergic receptor activation of ERK ²² Extra-nuclear estrogen signaling ⁶⁶	12.41	ESR1 EGFR CCND1 AKT1
13	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.41	AKT1 CCND1 ERBB2 ESR1 TP53
14	Cell cycle Regulation of G1/S transition (part 1) ²² Show member pathways Cell cycle ESR1 regulation of G1/S transition ²² Cell cycle Role of SCF complex in cell cycle regulation ²² Immune response MIF-JAB1 signaling ²² Mitotic Roles of Polo Like Kinases ⁶⁴	12.37	PGR ESR1 CDK4 CCND1
15	Focal adhesion ⁷⁴	12.28	ERBB2 EGFR CCND1 AKT1
16	Development Ligand-independent activation of ESR1 and ESR2 ²² Show member pathways Transcription CREB pathway ²² Transcription PPAR Pathway ²²	12.28	ESR1 ERBB2 EGFR CCND1 AKT1
17	p53 Signaling ⁶⁴ Show member pathways p53 Pathway ⁶⁷	12.2	AKT1 CCND1 CDK4 TP53
18	Colorectal Cancer Metastasis ⁶⁴	12.18	TP53 EGFR CCND1 AKT1
19	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	12.14	TP53 CDK4 CCND1 AKT1
20	Transcription Androgen Receptor nuclear signaling ²² Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²²	12.11	ERBB2 EGFR CCND1 AKT1
21	miRNA regulation of DNA damage response ⁷⁴ Show member pathways DNA damage response ⁷⁴	12.1	TP53 CDK4 CCND1 AKT1
22	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.09	TP53 ERBB2 EGFR CDK4 CCND1 AKT1
23	mTOR Signaling ⁶⁵	12.08	AKT1 EGFR ERBB2 TP53
24	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ⁶¹ Nuclear signaling by ERBB4 ⁶⁶	12.04	PGR ESR1 ERBB2 EGFR
25	Signaling by PTK6 ⁶⁶ Show member pathways PTK6 Activates STAT3 ⁶⁶ PTK6 Down-Regulation ⁶⁶ PTK6 Expression ⁶⁶ PTK6 promotes HIF1A stabilization ⁶⁶ PTK6 Regulates Proteins Involved in RNA Processing ⁶⁶ PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases ⁶⁶ PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 ⁶⁶ Signaling by Non-Receptor Tyrosine Kinases ⁶⁶	12.04	ERBB2 EGFR CDK4 CCND1 AKT1
26	MAPK Pathway ⁷⁰ Show member pathways Toll-like Receptor Pathway ⁷⁰	11.99	TP53 ERBB2 EGFR AKT1
27	Spinal cord injury ⁷⁴	11.95	TP53 EGFR CDK4 CCND1
28	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors ⁶⁶ Show member pathways Activation of the TFAP2 (AP-2) family of transcription factors ⁶⁶ Negative regulation of activity of TFAP2 (AP-2) family transcription factors ⁶⁶ TFAP2 (AP-2) family regulates transcription of cell cycle factors ⁶⁶ TFAP2 (AP-2) family regulates transcription of growth factors and their receptors ⁶⁶ TFAP2 (AP-2) family regulates transcription of other transcription factors ⁶⁶ TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation ⁶⁶	11.85	ESR1 ERBB2 EGFR
29	Small cell lung cancer ⁷⁴	11.85	TP53 CDK4 CCND1 AKT1
30	Retinoblastoma gene in cancer ⁷⁴	11.84	TP53 CDK4 CCND1
31	Regulation of nuclear SMAD2/3 signaling ⁶¹	11.75	ESR1 CBFB AKT1
32	Transcription Ligand-dependent activation of the ESR1/SP pathway ²² Show member pathways Development Ligand-dependent activation of the ESR1/AP-1 pathway ²²	11.73	ESR1 EGFR CCND1
33	Physico-chemical features and toxicity-associated pathways ⁷⁴	11.69	AKT1 EGFR ERBB2
34	Validated nuclear estrogen receptor alpha network ⁶¹	11.69	CCND1 ESR1 PGR
35	Integrated breast cancer pathway ⁷⁴	11.68	TP53 ESR1 EGFR CYP19A1 CDK4 CCND1
36	Pathways affected in adenoid cystic carcinoma ⁷⁴	11.66	TP53 ERBB2 AKT1
37	DYRK1A ⁷⁴	11.66	TP53 CDK4 CCND1
38	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	11.66	TP53 PGR ESR1 ERBB2 EGFR CDK4
39	Coregulation of Androgen receptor activity ⁶¹	11.65	KDM4C CCND1 AKT1
40	AP-1 transcription factor network ⁶¹	11.65	TP53 ESR1 CCND1 CBFB
41	Prader-Willi and Angelman syndrome ⁷⁴	11.64	TP53 CDK4 CCND1
42	Regulation of Telomerase ⁶¹	11.63	ESR1 EGFR CCND1 AKT1
43	Copper homeostasis ⁷⁴ Show member pathways Copper metabolism ⁷⁴ Defective SLC11A2 causes hypochromic microcytic anemia, with iron overload 1 (AHMIO1) ⁶⁶	11.62	TP53 CCND1 AKT1
44	Hepatitis C and hepatocellular carcinoma ⁷⁴	11.59	TP53 CCND1 AKT1
45	IL-2 Gene Expression in Activated and Quiescent T-Cells ⁶⁴ Show member pathways TOB in T-Cell Signaling ⁶⁴	11.59	ERBB2 EGFR CCND1 AKT1
46	ATF-2 transcription factor network ⁶¹	11.53	ESR1 CDK4 CCND1 CBFB
47	Head and neck squamous cell carcinoma ⁷⁴	11.5	TP53 ERBB2 EGFR CDK4 CCND1 AKT1
48	DNA damage_ATM/ATR regulation of G1/S checkpoint ²²	11.48	TP53 CDK4 CCND1
49	Inhibition of Signaling by Overexpressed EGFR ⁶⁶ Show member pathways Estrogen-dependent nuclear events downstream of ESR-membrane signaling ⁶⁶ Signaling by Overexpressed Wild-Type EGFR in Cancer ⁶⁶	11.43	EGFR CCND1 AKT1
50	Integrated cancer pathway ⁷⁴	11.39	TP53 CDK4 AKT1

Sources

GO Terms for Estrogen-Receptor Positive Breast Cancer

Cellular components related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cyclin D1-CDK4 complex	GO:0097128	8.92	CDK4 CCND1

Biological processes related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of gene expression	GO:0010629	9.92	TP53 PGR MIR125A ESR1 AKT1
2	positive regulation of G1/S transition of mitotic cell cycle	GO:1900087	9.73	EGFR CCND1 AKT1
3	cellular response to epidermal growth factor stimulus	GO:0071364	9.63	ERBB2 EGFR AKT1
4	positive regulation of miRNA maturation	GO:1903800	9.37	TP53 EGFR
5	positive regulation of RNA polymerase II transcription preinitiation complex assembly	GO:0045899	9.26	TP53 ESR1
6	response to UV-A	GO:0070141	9.1	EGFR CCND1 AKT1

Molecular functions related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	enzyme binding	GO:0019899	9.8	TP53 PGR KDM4C ESR1 EGFR CCND1
2	protein kinase activity	GO:0004672	9.76	HSPB8 ERBB2 EGFR CDK4 CCND1 AKT1
3	nitric-oxide synthase regulator activity	GO:0030235	9.1	ESR1 EGFR AKT1